Reports by Industry
Reports by Company
- Company Analysis(173)
- Company Profile(60)
Global Biosimilar Market Outlook 2022
Format : 
Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Sep, 2016| No. of Pages : 135
Please make your selection :
Electronic Access - Single User License
US$ 1500.00
CD-ROM Mail Delivery
US$ 1700.00
Hard Copy Mail Delivery
US$ 1700.00
Electronic Access - Multi-User License
US$ 2200.00
List of Figures:
Figure 3-1: Global - Biosimilars Market (Million US$), 2016 & 2022
Figure 4-1: Global - Population above 60 Years (Billion), 2013 & 2050
Figure 4-2: World's Best Selling Biologics and their Patent Expiry in the US & EU
Figure 5-1: Global - Biosimilars Market by Product Type (%), 2016
Figure 5-2: Global - Erythropoietin Biosimilars Market (Million US$), 2016 & 2022
Figure 5-3: Global - HGH Biosimilars Market (Million US$), 2016 & 2022
Figure 5-4: Global - G-CSF Biosimilars Market (Million US$), 2016 & 2022
Figure 5-5: Global - mAb Biosimilars Market (Million US$), 2016 & 2022
Figure 5-6: Global - Insulin Biosimilars Market (Million US$), 2016 & 2022
Figure 5-7: Global - Interferon Biosimilars Market (Million US$), 2016 & 2022
Figure 5-8: Global - Other Biosimilars Market (Million US$), 2016 & 2022
Figure 6-1: Global - Biosimilars Market by Key Geographies (%), 2016
Figure 6-2: Europe - Biosimilars Market (Million US$), 2016 & 2022
Figure 6-3: Europe - Biosimilars Market by Country (%), 2016
Figure 6-4: Germany - Biosimilars Market (Million US$), 2016 & 2022
Figure 6-5: France - Biosimilars Market (Million US$), 2016 & 2022
Figure 6-6: Italy - Biosimilars Market (Million US$), 2016 & 2022
Figure 6-7: Spain - Biosimilars Market (Million US$), 2016 & 2022
Figure 6-8: UK - Biosimilars Market (Million US$), 2016 & 2022
Figure 6-9: Asia Pacific - Biosimilars Market (Million US$), 2016 & 2022
Figure 6-10: Asia-Pacific - Biosimilars Market by Country (%), 2016
Figure 6-11: India - Biosimilars Market (Million US$), 2016 & 2022
Figure 6-12: China - Biosimilars Market (Million US$), 2016 & 2022
Figure 6-13: Japan - Biosimilars Market (Million US$), 2016 & 2022
Figure 6-14: North America - Biosimilars Market (Million US$), 2016 & 2022
Figure 6-15: North America - Biosimilars Market by Country (%), 2016
Figure 6-16: US - Biosimilars Market (Million US$), 2016 & 2022
Figure 6-17: Canada - Biosimilars Market (Million US$), 2016 & 2022
Figure 6-18: Rest of the World - Biosimilars Market (Million US$), 2016 & 2022
Figure 7-1: Global - Biosimilars Market by Applications (%), 2016
Figure 7-2: Global - Number of New Cancer Cases (Million), 2015 & 2025
Figure 7-3: Oncology - Biosimilars Market (Million US$), 2016 & 2022
Figure 7-4: Blood Disorders - Biosimilars Market (Million US$), 2016 & 2022
Figure 7-5: Other Diseases - Biosimilars Market (Million US$), 2016 & 2022
Figure 11-1: Market Share of Major Players in the Biosimilar Industry, 2015
List of Tables:
Table 5-1: Global - Biosimilar EPOs Approved for Marketing
Table 5-2: Global - Biosimilar EPOs in Pipeline
Table 5-3: Global - Biosimilar HGH Approved for Marketing
Table 5-4: Global - Biosimilar HGH in Pipeline
Table 5-5: Global - Biosimilar G-CSF Approved for Marketing
Table 5-6: Global - Biosimilar G-CSF in Pipeline
Table 5-7: Global - Biosimilar mAbs Approved for Marketing
Table 5-8: Global - Biosimilar mAbs in Pipeline
Table 5-9: Global - Biosimilar Insulin Approved for Marketing
Table 5-10: Global - Biosimilar Insulin in Pipeline
Table 5-11: Global - Biosimilar Interferons Approved for Marketing
Table 5-12: Global - Biosimilar Interferons in Pipeline
Table 9-1: Global - Major M&A in the Biosimilar Industry (2014-2016)
Table 11-1: Biocad - Major Biosimilars Approved for Marketing
Table 11-2: Biocad - Major Biosimilars in Pipeline
Table 11-3: Celltrion Inc. - Revenue (Million US$), 2013, 2014 & 2015
Table 11-4: Celltrion Inc. - Major Biosimilars Approved for Marketing
Table 11-5: Celltrion Inc. - Major Biosimilars in Pipeline
Table 11-6: Dong-A Socio Group - Revenue (Million US$), 2013, 2014 & 2015
Table 11-7: Dong-A Socio Group - Major Biosimilars in Pipeline
Table 11-8: Pfizer Inc. - Revenue (Million US$), 2013, 2014 & 2015
Table 11-9: Pfizer Inc. - Major Biosimilars Approved for Marketing
Table 11-10: Pfizer Inc. - Major Biosimilars in Pipeline
Table 11-11: Intas Pharmaceutical Ltd. - Revenue (Million US$), FY2013, FY2014 & FY2015
Table 11-12: Intas Pharmaceuticals Ltd. - Major Biosimilars Approved for Marketing
Table 11-13: Intas Pharmaceuticals Ltd. - Major Biosimilars in Pipeline
Table 11-14: Sandoz International GmbH - Revenue (Million US$), 2013, 2014 & 2015
Table 11-15: Sandoz International GmbH - Major Biosimilars Approved for Marketing
Table 11-16: Sandoz International GmbH - Major Biosimilars in Pipeline
Table 11-17: Stada Arzneimittel AG - Group Sales (Million US$), 2013, 2014 & 2015
Table 11-18: Stada Arzneimittel AG - Major Biosimilars Approved for Marketing
Table 11-19: Stada Arzneimittel AG - Major Biosimilars in Pipeline
Table 11-20: Teva Pharmaceutical Industries Ltd. - Net Sales (Million US$), 2013, 2014 & 2015
Table 11-21: Teva Pharmaceutical Industries Ltd. - Major Biosimilars Approved for Marketing
Table 11-22: Amgen Inc. - Total Company Revenue (Million US$), 2013, 2014 & 2015
Table 11-23: Amgen Inc. - Major Biosimilars in Pipeline
Table 11-24: Biocon - Revenue (Million US$), FY2014, FY2015 & FY2016
Table 11-25: Biocon - Major Biosimilars Approved for Marketing
Table 11-26: Biocon - Major Biosimilars in Pipeline
Not able to find data you are looking for? Ask our Research Analyst.
media citation
- testtest
19 Jan, 2024 - Yourstory.com News @ Foodtech startup Swiggy launches Health Hub in Chennai
23 Mar, 2021 - Yourstory.com News @ Zomato forays into dietary supplements, makes its own 'made in India' brand
16 Mar, 2021 - View more
get in touch
Copyright © 2018, RNCOS, 2002-2018
About Us
Terms & Policy
Contact